Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Tolerance and alternative kinase inhibitors in CLL
Intolerance is the most common reason for discontinuing PI3K or BTK inhibitor drugs used for the treatment of chronic lymphocytic leukemia (CLL), and it has been found that the intolerant patient popu... Author: VJHemOnc Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts

An unmet need in CLL: patients failing ibrutinib and idelalisib
Relapse and failure of ibrutinib and idelalisib regimens in chronic lymphocytic leukaemia (CLL) is becoming an increasingly common. Here, Christopher Fox, MBChB(Hons), MRCP FRCPath, of Nottingham Univ... Author: VJHemOnc Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts

Identifying TP53 disruptions: a diagnostic measure in CLL
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and costly. Here, Anna Schuh, MD, PhD, MRCP,... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Velocity Vlog: Transforming the Diagnosis and Treatment of CLL
Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL). Despite this, treatment challenges remain, particula... Author: imedex Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospi... Author: VJHemOnc Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Next steps in gaining CLARITY on CLL
With new developments in the treatment of patients with chronic lymphocytic leukemia (CLL), is there a possibility of eradicating the disease? In this interview, Francesco Forconi, MD, DM, PhD, FRCPat... Author: VJHemOnc Added: 02/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 27, 2018 Category: Cancer & Oncology Source Type: podcasts

CAR T-cells for CLL: ibrutinib pre-treatment, T-cell quality and future predictions
We know that CAR T-cell therapy is effective in the treatment of chronic lymphocytic leukemia (CLL); however, a current limitation is the collection of high quality originator T-cells from patients. S... Author: VJHemOnc Added: 02/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 19, 2018 Category: Cancer & Oncology Source Type: podcasts

MURANO study: exciting times in CLL
Data from the Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and ... Author: VJHemOnc Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts

TP53 mutations in CLL: a large retrospective analysis
Little is known about TP53 mutations and their association with adverse prognosis and chemotherapy resistance in chronic lymphocytic leukemia (CLL). Here, Florence Cymbalista, MD, of Avicenne Hospital... Author: VJHemOnc Added: 02/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts

ASH 2017: combination therapy for CLL highlights
Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Colog... Author: VJHemOnc Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Bendamustine plus rituximab vs. standard therapy for advanced CLL
Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Ho... Author: VJHemOnc Added: 02/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 5, 2018 Category: Cancer & Oncology Source Type: podcasts

Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Data from recent studies indicate that PD-1 and PD-L1/PD-L2 mediate immune evasion in chronic lymphocytic leukemia (CLL), highlighting their importance in this malignancy. In this interview, Anthony M... Author: VJHemOnc Added: 02/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 2, 2018 Category: Cancer & Oncology Source Type: podcasts

Safety of Chronic Lymphocytic Leukemia Combination Therapy - Fair Number of Hematologic & Non-Hematologic Adverse Effects
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On Hematology in Huntington Beach to talk about the safety of chronic lymphocytic leukemia combina... Author: moasc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts

Retrospective multicenter analysis of venetoclax-treated CLL patients
Venetoclax is approved for the treatment of relapsed/refractory del17p chronic lymphocytic leukemia (CLL) and has shown activity in patients following the failure of kinase inhibitors. However, there ... Author: VJHemOnc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts

Front-line use of ibrutinib for CLL in a real-world setting
Ibrutinib is approved for all lines of therapy in chronic lymphocytic leukemia (CLL); however, front-line ibrutinib studies have primarily enrolled older low-risk patients, which are not representativ... Author: VJHemOnc Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts